



Q2 2021 Financial Results

Safe Harbor Statement

Certain statements contained in this presentation are "forward-looking statements" about future events and expectations. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, the continuing impact of the COVID-19 outbreak on the economy and our operations (including temporary clinic closures, shortened business hours and reduced patientdemand), our failure to develop or acquire company-owned or managed clinics as rapidly as we intend, our failure to profitably operate company-owned or managed clinics, and the other factors described in "Risk Factors" in our Annual Report on Form 10-W as filed with the SEC for the year ended December 31, 2020, as updated or revised for any material changes described in any subsequently-filed Quarterly Reports on Form 10-Q or other SEC filings. We anticipate filing our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 on or around August 6, 2021. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statemen

Business Structure

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.



Revolutionizing Access to Chiropractic Care

As an essential healthcare service, The Joint Chiropractic's mission is to improve the quality of life through routine and affordable chiropractic care.

BUILD BRAND



INCREASE AWARENESS



DELIVER EXCEPTIONAL PATIENT EXPERIENCE



OPEN NEW CLINICS





Record Breaking Quarter

64%

Increase in system-wide sales Q2 2021 over Q2 2020

53%

Increase in comp sales¹ for all clinics >13 months in operation Q2 2021 over Q2 2020

44%

Increase in comp sales¹ for all clinics >48 months in operation Q2 2021 over Q2 2020

	Q2 2021	Change from Q2 2020					
Revenue	\$20.2M	Up 61%					
Op. Income	\$2.0M	Up 687%					
Adjusted EBITDA ²	\$3.8M	Up 237%					
Unrestricted cash \$18.5M at June 30, 2021, compared to \$20.6M Dec. 31, 2020							




¹Comparable sales include only the sales from clinics that have been open at least 13 or 48 full months and exclude any clinics that have permanently closed.

² Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

Record 41 Clinics Opened in Q2 2021 Driving to 1,000 Clinics by the End of 2023

	Q2 2020	Q2 2021
Franchise Licenses Sold	11	63
Total New Franchised Clinics Opened	12	36
Greenfield Clinics Opened	1	5
Franchised Clinics Acquired	0	8
Clinics in Development	209	282





Bringing Chiropractic Care to Military Bases






Natural Extension of Commitment to Military

- 33M active-duty and retired service members and their families, along with disabled veterans and government civilians who work on military installations
- Initial target clinic sites: Phoenix, Tampa, and New Jersey
- AAFES operating
 - 4,900+ facilities
 - 30+ countries, 50 states, 4 U.S. territories and D.C.




Record 63 Franchise Licenses Sold in Q2 2021

Franchise Licenses Sold Annually



Clinics in Active Development¹



Gross Cumulative Franchise Licenses Sold¹



- 87% sold by RDs in 2021
- 70% of clinics supported by 21 RDs at June 30, 2021
- RDs cover 59% of Metropolitan Statistical Areas (MSAs) at June 30, 2021



¹ Of the 1,051 franchise licenses sold as of June 30, 2021, 282 are in active development, 633 are currently operating and the balance represents terminated/closed licenses.

The Joint Corp. | NASDAG: JYNT © 2020 The Joint Corp. All Rights Reserved.

Surging New Patient Acquisition in Q2



Multiple Factors Driving Momentum on New Patient Counts

- April, May, June: Monthly records for New Patient acquisition
- May: External campaign promoting chiropractic and posture (see infographic)
- June: Win-back direct marketing campaign to inactive patients
- Ongoing: Improved digital lead nurturing at the clinic level



Successfully Launched New IT Platform

Successfully launched Axis 1.0 in July







Record Q2 2021 Financial Results

\$ in M ¹	Q2 2021	Q2 2020	Differe	nces
Revenue	\$20.2 11.4 8.8	\$12.6 6.9 5.7	\$7.6 4.5 3.1	61% 67% 53%
Cost of revenue	2.0	1.4	0.6	49%
Sales and marketing	3.1	1.8	1.3	76%
Depreciation and amortization	1.4	0.7	0.7	108%
G&A	11.6	8.5	3.1	36%
Operating Income	2.0	0.3	1.7	687%
Tax Benefit	0.7	(0.1)	0.8	8X
Net Income/(Loss)	2.7	0.1	2.6	26X
Adj. EBITDA ²	3.8	1.1	2.6	237%



¹ Due to rounding, numbers may not add up precisely to the totals. ² Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

The Joint Corp. | NASDAG: JYNT

YTD June 30, 2021 Financial Results

\$ in M ¹	YTD June 30, 2021	YTD June 30, 2020	Differe	ences
Revenue	\$37.8 20.9 16.9	\$26.2 14.1 12.1	\$11.6 6.8 4.8	44% 48% 40%
Cost of revenue	3.8	2.9	0.9	33%
Sales and marketing	5.6	3.8	1.8	46%
Depreciation and amortization	2.6	1.3	1.3	94%
G&A	21.7	17.2	4.5	26%
Operating Income	4.0	1.0	3.0	296%
Tax Benefit	1.0	(0.1)	1.1	11X
Net Income/(Loss)	5.0	0.9	4.1	4X
Adj. EBITDA ²	7.2	2.8	4.4	160%

Unrestricted cash \$18.5M at June 30, 2021, compared to \$20.6M at Dec. 31, 2020



¹ Due to rounding, numbers may not add up precisely to the totals. ² Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

The Joint Corp. | NASDAQ: JYNT

Raising All Elements of 2021 Guidance

\$ in M	2020 Actual	2021 Low Guidance	2021 High Guidance	Midpoint 2021 vs 2020
Revenues ¹	\$58.7	\$77.0	\$79.0	Up 33%
Adjusted EBITDA ^{1,2}	\$9.1	\$12.5	\$13.5	Up 43%
New Franchised Clinic Openings ¹	70	90	110	Up 57%
New Company-owned/Managed Clinics ^{1,3}	4	25	35	7.5X greater



¹ The guidance provided on May 6, 2021: Revenue expected between \$73.5M and \$77.5M; d Adjusted EBITDA expected between \$11.0M and \$12.5M; new franchised clinic openings between 80 and 100, and new company-owned/managed clinics between 20 and 30.


The Joint Corp. | NASDAG: JYNT © 2021 The Joint Corp. All Rights Reserved.

² Reconciliation of Adjusted EBITDA to GAAP earnings is included in the appendix.

³ Through a combination of both greenfields and buybacks.

Substantial Opportunity for Market Share Growth

- Annual spending on back pain: \$90B¹
- Chiropractic care: \$18B²
- Total chains make up ~3% of chiropractic³
- By contrast, dentistry chains (DSOs) account for nearly 12%⁴





¹ NCBI US National Library of Medicine Bureau of Labor Statistics, U.S. Department of Labor, Occupational Outlook Handbook, 2016-17 Edition | ² IBIS US Industry Report, Chiropractors in the US, April 2021 | ³ Internal Chiropractic Competitive Analysis, August 2019 | ⁴ Apex Reimbursement Specialists, Inc., 2018


The Joint Corp. | NASDAG: JYNT © 2021 The Joint Corp. All Rights Reserved.

Resilient Business Model Drives Long-term Growth

People will continue to seek more noninvasive, holistic ways to manage their pain.

We'll be there to treat them.

The Joint Corp. 10-yr. CAGR 70%¹ vs. Industry CAGR 5.4%^{2*}





¹ For the period ended Dec. 31, 2020 | ² June 2021 Kentley Insights Chiropractic Care Market Research Report

Non-GAAP Measure Definition

This presentation includes non-GAAP financial measures. System-wide sales include sales at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.


EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the Company's underlying operating performance and operating trends than GAAP measures alone. Reconciliations of net loss to EBITDA and Adjusted EBITDA are presented where applicable. The Company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The Company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase net gain, gain/(loss) on disposition or impairment, and stock-based compensation expenses.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are frequently used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the Company's financial statements filed with the SEC.



The Joint Corp. | NASDAG: JYNT © 2021 The Joint Corp. All Rights Reserved.


Q2 2021 Segment Results



Total Revenues
Total Operating Costs
Operating Income (Loss)
Other Income (Expense), net
Income (Loss) Before Income Tax Expense
Total Income Taxes
Net Income (Loss)
Net Interest
Income Taxes
Total Depreciation and Amortization Expense
EBITDA
Stock Based Compensation Exp
Bargain Purchase Gain
(Gain) Loss on Disposition/Impairment
Acquisition Expenses
Adjusted EBITDA

rporate Clinics	anchise erations	allocated orporate		ne Joint solidated
\$ 11,432	\$ 8,785	\$ 1	s	20,219
 (9,607)	(4,903)	 (3,674)		(18,184)
1,825	 3,882	(3,673)		2,034
(2)	-	(14)		(16)
1,823	 3,882	(3,687)		2,018
-	 -	(666)		(666)
1,823	3,882	(3,021)		2,684
2	 _	14		16
-	-	(666)		(666)
 1,248	0	 195		1,443
3,073	3,883	(3,478)		3,477
-	-	284		284
-	-	_		-
(44)	-	_		(44)
-	-	39		39
3,029	3,883	(3,155)		3,756

YTD June 30, 2021 Segment Results



Total Revenues
Total Operating Costs
Operating Income (Loss)
Other Income (Expense), net
Income (Loss) Before Income Tax Expense
Total Income Taxes
Net Income (Loss)
Net Interest
Income Taxes
Total Depreciation and Amortization Expense
EBITDA
Stock Based Compensation Exp
Bargain Purchase Gain
(Gain) Loss on Disposition/Impairment
Acquisition Expenses
Adjusted EBITDA

rporate Clinics		Franchise Operations		allocated orporate	he Joint nsolidated
\$ 20,901	\$	16,862	\$	4	\$ 37,767
 (17,726)		(9,132)		(6,902)	(33,760)
3,175		7,730		(6,899)	4,006
(5)		-		(33)	(38)
3,170		7,730		(6,931)	3,969
-		-		(1,030)	(1,030)
3,170		7,730		(5,901)	4,999
5		-		33	38
-		-		(1,030)	(1,030)
 2,342		1		271	2,613
5,516		7,731		(6,628)	6,619
-		-		530	530
-		-		-	-
21		-		-	21
 -		-		45	45
5,537		7,731		(6,052)	7,215

GAAP – Non-GAAP Reconciliation

		rter Ending 03/31/2020	Qu	arter Ending 06/30/2020		arter Ending 09/30/2020	Qu	Jarter Ending 12/31/2020		Qu.	arter Ending 03/31/2021	Qu	arter Ending 06/30/2021	
	(Q1-20		Q2-20	(Q3-20		Q4-20	FY20		Q1-21		Q2-21	FY21
Total Revenue		13,644		12,590		15,411		17,038	58,683		17,548		20,219	37,767
Total Cost of Revenue		1,486		1,368		1,712		1,941	6,507		1,765		2,039	3,804
Gross Profit	\$	12,158	\$	11,222	\$	13,698	\$	15,097	\$52,176	\$	15,783	\$	18,180	\$33,963
Sales & Marketing		2,055		1,784		1,846		2,120	7,804		2,489		3,133	5,622
Depreciation/Amortization Expense		654		693		714		673	2,734		1,170		1,443	2,613
Other Operating Expenses		8,695		8,487		9,433		9,527	36,142		10,186		11,611	21,798
Total Other Income (Expense)		(4)		(25)		(26)		(26)	(82)		13		25	38
Total Income Taxes		(66)		118		76		(7,882)	(7,755)		(364)		(666)	(1,030)
Net Income (Loss)	\$	815	\$	116	\$	1,604	\$	10,633	\$13,167	\$	2,314	\$	2,684	\$ 4,998
Net Interest		4		25		26		24	79		22		16	38
Income Taxes		(66)		118		76		(7,882)	(7,755)		(364)		(666)	(1,030)
Depreciation and Amortization Expense		654		693		714		673	2,734		1,170		1,443	2,613
EBITDA	\$	1,408	\$	952	\$	2,420	\$	3,447	\$ 8,227	\$	3,142	\$	3,477	\$ 6,619
Stock Based Compensation		250		216		212		207	886		246		284	530
Bargain Purchase Gain		-		-		-		-	-		-		-	-
(Gain) Loss on Disposition/Impairment		1		(55)		-		2	(51)		65		(44)	21
Acquisition Expenses		-		-		-		42	42		6		39	45
Adjusted EBITDA	\$	1,659	\$	1,113	\$	2,632	\$	3,698	\$ 9,103	\$	3,459	\$	3,756	\$ 7,215



The Joint Corp. Contact Information



Peter D. Holt, President and CEO
peter.holt@thejoint.com
The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



Jake Singleton, CFO
jake.singleton@thejoint.com
The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



Kirsten Chapman, LHA Investor Relations
thejoint@lhai.com
LHA Investor Relations | One Market Street, Spear Tower, Suite 3600, San Francisco, CA 94105 | (415) 433-3777









The Joint Corp. | NASDAQ: JYNT